A3P Biomedical focuses on advancing the early detection of aggressive prostate cancer, which is the most prevalent cancer among men worldwide. Their approach emphasizes the importance of early diagnosis for effective treatment outcomes. The company has engaged over 90,000 participants in clinical studies, demonstrating their commitment to research and validation. Their technology has shown promising results, with findings indicating that 41-89% of more aggressive cancers can be identified earlier, while also reducing unnecessary biopsies by 37-52%. This not only enhances patient care but also contributes to lowering overall healthcare costs by 8-28%.

The company has made significant strides in the development and validation of their flagship product, Stockholm3, which has been launched in Germany and is part of a strategic partnership in Switzerland. The effectiveness of Stockholm3 has been independently validated at the prestigious Martini Klinik, underscoring its reliability and potential impact on prostate cancer diagnosis. A3P Biomedical's innovative approach aims to transform the landscape of prostate cancer detection, ultimately improving patient outcomes and optimizing healthcare resources.

Sweden

The commercially available Stockholm3- test, is a blood-test for early detection of prostate cancer.  A3P Biomedical’s Stockholm3 test, combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at early stage.

Kungsgatan 24, Stockholm, Stockholm County 111 35, SE

A3P Biomedical

Company Details